This announcement is made by Leoch International Technology Limited The board of directors of the Company announces that Mr. LU Zhiqiang ("Mr. LU") has been appointed as an independent non-executive Director and a member of each of the Audit Committee and Nomination Committee of the Company with effect from 21 March 2022. Mr. LU, aged 47, was Asia Fellow in Harvard University from August 2018 to. July 2020. Mr. LU holds a Master Degree of Business Administration from Central State University of the United States of America in 2001, a Bachelor Degree of Engineering and a Bachelor Degree of Industry from Nanchang Hangkong University of The People's Republic of China in 1996 and 1997 respectively. Mr. LU attended the program of a Master of Science Degree in International Purchasing & Supply Chain Management organised by Audencia NANTES.Ecole de Management in 2002. Mr. LU is currently an executive director and the chief executive officer of Hong Kong Life Sciences and Technologies Group Limited whose issued shares were listed on GEM of the Stock Exchange under stock code: 8085 but were delisted on 14 September 2020. He served as an executive director of Extrawell Pharmaceutical Holdings Limited whose issued shares are listed on the Main Board of the Stock Exchange under stock code: 858 from 27 January 2017 to 26 January 2020. Under the terms of his service agreement with the Company, his office shall commence on 21 March 2022 for a term of two years, which is subject to termination by either party giving not less than two months' prior written notice. In accordance with the articles of association of the Company, Mr. LU will be subject to re-election at the general meeting of the Company after his appointment.
Mr. LU is entitled to Director's fee of HKD 240,000 per annum. The above emolument of Mr. LU has been determined by the Board with reference to the prevailing market condition, his experience, his role and responsibilities and the Company's remuneration policy. Such remuneration has been recommended by the Remuneration Committee of the Company and approved by the Board.